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Key points 
Solid pre-clinical data suggests Nogo-A-neutralization as a potential therapeutic approach for neuro-
inflammatory and demyelinating pathology. Nogo-A-antibodies are now in early clinical development 
for multiple sclerosis (MS). Their potential to boost axonal regeneration and compensatory fiber 
growth as well as myelin repair makes them an attractive candidate to treat also progressive MS in 
which neurodegeneration and chronic demyelination are hallmarks. 
  
Abstract 
Most of the current therapies as well as many of the clinical trials for Multiple Sclerosis (MS) target 
the inflammatory autoimmune processes, but less than 20% of all clinical trials investigate potential 
therapies for the chronic progressive disease stage of MS. The latter is responsible for the steadily 
increasing disability in many patients, and there is an urgent need for novel therapies that protect 
nervous system tissue and enhance axonal growth and/or remyelination. As outlined in this review, 
solid pre-clinical data suggest neutralization of the neurite outgrowth inhibitor Nogo-A as a potential 
new way to achieve both, axonal and myelin repair. Several phase I clinical studies with anti-Nogo-A 
antibodies have been conducted in different disease paradigms including MS and spinal cord injury. 
Data from spinal cord injury and amyotrophic lateral sclerosis (ALS) trials accredit a good safety 
profile of high doses of anti-Nogo-A-antibodies intravenously or intrathecally. An antibody against a 
Nogo receptor subunit, LINGO-1, was recently shown to improve outcome in acute optic neuritis in a 
phase II study. Nogo-A suppressing antibodies could be novel drug candidates for the relapsing as 
well as the progressive MS disease stage. In this review, we summarize the available pre-clinical and 
clinical evidence on Nogo-A and elucidate its potential use as a therapy for progressive MS. 
  
1. Introduction 
Multiple sclerosis (MS) is the leading cause of non-traumatic neurological disability in young adults in 
Europe and America [1]. It is an inflammatory demyelinating disease of the central nervous system 
(CNS) [2]. The causes of MS are not yet fully understood, but a complex genetic trait and several 
environmental risk factors have been identified, and the prevailing view suggests an autoimmune 
etiology [3]. 
In 85% of cases, the disease begins with a relapsing remitting course (RRMS), during which bouts of 
inflammatory disease activity with transient blood brain-barrier (BBB) opening are observed. In most 
patients, RRMS is followed by a progressive phase. This phase is defined by a disappearance of 
relapses and a gradually increase in disability without remission; finally, many patients become 
wheelchair bound. This form is referred to as secondary progressive MS (SPMS). In 10% of cases, 
patients suffer from a primary progressive disease course with no superimposed neuro-inflammatory 
bouts, referred to as primary progressive MS (PPMS) [4]. Thus, approximately 95% of patients are 
affected by extensive neurodegeneration sooner or later in the disease course. 
However, no therapies are currently available that simultaneously dampen the inflammatory 
reactions and also protect the axons from degeneration [5]. Over the last 20 years, several 
compounds have been well-established in the treatment regimen of MS patients: interferon beta, 
glatiramer acetate, teriflunomide, dimethyl fumarate, natalizumab, fingolimod, alemtuzumab and 
mitoxantrone [6]. All of these have mainly immunomodulatory or immunosuppressive properties and 
are therefore more effective for the treatment of early MS disease stages where acute inflammation 
is predominant [7, 8]. Although interferon beta and mitoxantrone were investigated in progressive 
MS, final conclusions about their effectiveness in treating this chronic disease stage are still unclear 
and the effect is at best moderate [9, 10]. Another compound was approved in 2016: daclizumab, a 
humanized IgG against interleukin-2 receptor alpha chain on T cells [11, 12]. Ocrelizumab, a 
humanized anti-CD20 IgG [13, 14], is at the edge to clinical approval. Ocrelizumab is notably the first 
treatment option for PPMS (reviewed in [15]). 
This is a breakthrough, in particular with regard to disappointing trials during the last 25 years 
assessing the effectiveness of drug candidates in progressive MS stages [16]. Important reasons for 
failure of these trials include that they only targeted the adaptive immune mechanisms. Besides that, 
the design of these studies was not suited to identify effects in patients suffering from progressive 
MS [17]. The difficulties in testing potential therapies for progressive MS are as well reflected by the 
fact that only a small amount of all current clinical MS trials investigates interventions for the 
progressive stage. This is shown by a systematic search on clinicaltrials.gov detecting as few as 17.3% 
of all studies investigating such interventions (126 of 727 studies, search string: “Multiple Sclerosis 
OR MS”, last search date: 01st of March, 2016). A further complication at the preclinical level is that 
no proper animal model is available for progressive MS [18]. However, many lessons were learned 
from preclinical [18] and clinical trials [16]. Additionally, promising new drug candidates are currently 
in development (reviewed in [19]). 
One such candidate, which is in early clinical development for progressive (and relapsing) MS, is an 
antibody against the protein Nogo-A. In this review, we give a brief overview on this myelin-
associated, nerve fiber growth inhibitory  protein and its receptors and we summarize its relation to 
demyelinating, neuro-inflammatory and neurodegenerative pathology from clinical and preclinical 
evidence. 
2. Multiple sclerosis leads to extensive neurodegeneration 
2.1. The pathogenic cascade leading to neurodegeneration 
Axonal and neuronal injury is a common phenomenon in acute, relapsing MS lesions as shown by 
histological analysis of MS tissue [20, 21], MRI [22] and magnetic resonance spectroscopy [23]. The 
prevailing view is that infiltration of immune cells and subsequent demyelination are responsible for 
this axonal loss [24]. 
The early pathological processes trigger a cascade of events which often lead to chronic 
demyelination and neurodegeneration [25], the hallmarks of the secondary progressive disease 
stage. The chronic inflammation results in microglia and macrophage activation producing reactive 
oxygen and nitrogen species (ROS/NOS) which can lead to mitochondrial damage [26, 27] (reviewed 
in [28]), metabolic stress, protein misfolding and deceased axonal transport [29, 30]. Accumulating 
evidence suggests genuine hypoxia as another mechanism contributing to the tissue injury in acute 
as well as chronic MS lesions [31-33]. 
2.2. Chronic demyelination amplifies neurodegeneration 
The demyelinated tissue often fails to successfully repair the myelin leading to chronically denuded 
axons [34, 35]. This is in part due to failure of oligodendrocyte precursor differentiation and 
myelination [35]. This chronic demyelination can lead to a lack of support function from the 
oligodendrocytes/myelin sheaths which ultimately results in axonal decline [36, 37]. Ion channel 
redistribution is yet another sequel of chronic demyelination: different neuronal ion channels show 
redistribution along axons to compensate ionic imbalance, e.g. voltage-gated sodium channels 
(Nav1.2 and Nav1.6) [38], acid-sensing ion channel 1 (ASIC1) [39, 40], and transient receptor 
potential cation channel subfamily M member 4 (TRPM4) [41] (reviewed in [42]). This channel 
redistribution results in ionic imbalance further perpetuating tissue damage [42]. 
All above-mentioned destructive processes can be amplified by pre-existing brain injuries and factors 
associated with brain-ageing [25]. Resulting lesions show slow expansion leading to general CNS 
tissue atrophy [43]. This can result in extensive axonal injury which can be as high as 70% of axons 
being destroyed in chronic white matter lesions of severely disabled MS patients [44, 45]. In fact, the 
progressive neuronal degeneration closely correlates with the progressive neurological decline [46]. 
2.3. Therapeutic opportunities 
This cascade of pathogenic events culminating in extensive axonal decline offers therapeutic 
opportunities. One of them is the enhancement of neuronal plasticity and regeneration of neurons 
and axons. The promotion of remyelination by recruitment of the oligodendrocyte precursor pool is 
yet another one. Important for therapeutic approaches is that successful remyelination was shown to 
stop the progressive axonal loss [47, 48]. 
3. The Nogo-A protein: its distribution and receptors 
One of the drug candidates in early clinical development which would be able to induce axonal 
regeneration and remyelination is an antibody against the neurite outgrowth inhibitory protein 
Nogo-A [49]. The Nogo-A protein was first characterized as an inhibitory protein for neurite 
outgrowth in brain and spinal cord myelin in vitro in 1988 [50]; its cDNA was cloned in 2000 [51, 52]. 
It downregulates neuronal growth, stabilizes the CNS wiring and restricts plasticity in the adult CNS 
[53]. Nogo-A is a member of the reticulon family and is highly conserved across species. Three 
isoforms are generated by alternative splicing; A, B and C, but only Nogo-A has been shown to have 
inhibitory effects in the CNS. Nogo-A is present in various cell types of the CNS, including 
oligodendrocytes and neurons [54]. It is localized at the cell surface and in the endoplasmatic 
reticulum (ER) and can have different membrane topologies with regard to a cytoplasmic versus 
extracellular position of the N terminus [55]. 
Two inhibitory regions have been identified in this 1200 amino acid long protein, Nogo-A-Δ20 (amino 
acids 544–725 in rat Nogo-A) and Nogo-66 (amino acids 1055-1079 in rat Nogo-A, links the two long 
hydrophobic stretches which span the cell membrane) [49]. The Nogo receptor 1 (NgR1) has been 
described as a receptor for Nogo-66 [56]. Upon Nogo-A-binding, NgR1 associates with the 
transmembrane proteins leucine rich repeat and Immunoglobin-like domain-containing protein 1 
(LINGO-1) and p75 or tumour necrosis factor-α (TNFα) receptor superfamily member 19 (TROY) to 
form a multisubunit receptor complex [49, 57]. The sphingosine-1-phosphate receptor 2 (S1PR2) is a 
receptor for Nogo-A-Δ20 [58] (Fig. 1a). 
Although Nogo-66 and Nogo-A-Δ20 bind to distinct receptors, it was demonstrated that they 
modulate the same intracellular signaling pathway: ras homolog gene family member A (RhoA) and 
rho-associated protein kinase (ROCK) [57] (Fig. 1d). The intracellular changes induced by the signaling 
cascade include reduced growth of actin filaments, collapse of the growth cone, destabilization of 
microtubules, and downregulation of growth genes in the neuronal cell body [57, 59]. Paired 
Immunoglobulin-like receptor B (PirB) is an alternative receptor for Nogo-66. This receptor is 
expressed in many parts of the CNS at low levels but its relevance for signaling might be restricted to 
neural development or after ischemia [60]. 
LINGO-1 is a co-receptor for NgR1 upon Nogo-A binding (Fig. 1a). It is expressed exclusively on 
oligodendrocytes and neurons and it is upregulated upon CNS injury across various animal models 
and human CNS diseases [61]. Antagonization of LINGO-1 has been shown to be beneficial in various 
animal models in terms of axonal regeneration and remyelination [61]. However, as LINGO-1 is 
distributed more widely in the CNS than NgR1 [62], other ligands might exist besides Nogo-A and 
NgR1. Comparison of the effects of LINGO-1 neutralization to those of Nogo-A neutralization is 
therefore of great interest (Table 1). Moreover, Nogo-A, like LINGO-1, is largely expressed in the CNS 
representing a mostly CNS-specific drug target. 
Besides Nogo-A, the myelin proteins myelin-associated glycoprotein (MAG) and oligodendrocyte-
myelin glycoprotein (OMgp) are also ligands for NgR1 and were also reported to have neurite growth 
inhibitory activity in vitro. Not much is known about their in vivo functions in the context of neurite 
growth [63]. Nogo-A is by far the best studied one, and its extensive characterization suggests an 
important role during different neurodegenerative disorders [64, 65]. 
4. Nogo-A is an inhibitor of nerve fiber growth and regeneration 
In neuronal development, Nogo-A acts as a regulator of axonal growth, branching and fasciculation 
[66]. It also regulates the internode length and Ranvier node formation during myelin formation 
[67].Nogo-A is involved in the termination of the critical plastic period in several regions of the 
postnatal CNS [49, 53]. In the adult CNS, Nogo-A takes part in the stabilization of the structure and 
wiring of the CNS by restricting neurite growth to short distances. However, this growth restricting 
function of Nogo-A also inhibits regenerative and longer-range plastic events following injury or 
disease [53]. Suppressing the actions of Nogo-A by different means enhances plasticity and axonal 
regeneration, e.g. in rodent and monkey models of spinal cord injury and stroke; genetic Nogo-
deletion, Nogo-neutralizing antibodies, auto-immunization with Nogo-A, a blocking Nogo receptor 
fusion protein or a Nogo receptor blocking peptide have been used in these animal models (reviewed 
in [53]). 
Throughout these studies, Nogo-A-neutralization enhanced regrowth and compensatory sprouting of 
functionally important fiber systems such as the corticospinal tract as well as anatomical plasticity on 
different levels. At the same time, animals consistently showed significant functional recovery, e.g. in 
locomotion, skilled stepping over irregular ladders, balance or fine forepaw movements during 
grasping [53]. These beneficial effects appeared within 2 – 4 weeks after the treatment and, at least 
in spinal cord injury, seemed to be more efficient in acute settings [68]. However, blocking Nogo-A 
with NgR1-Fc fusion protein enhanced anatomical and functional recovery also when administered 
several months after spinal cord trauma [69]. In stroke, even treatment in chronic stages after large 
ischemic cortical strokes led to improved functional recovery and increased axonal sprouting [70]. 
Furthermore, the antibody treatment also had positive effects on stroke recovery in aged rats [71]. 
Of note, transient pharmacogenetic blockade of the newly grown midline-crossing corticospinal 
fibers after stroke abrogated the recovered grasping function [72]. This shows that newly grown 
fibers are indeed responsible for improved recovery after anti-Nogo-A antibody treatment. Especially 
important regarding future human use of these antibodies are the observations that neurological 
adverse effects like enhanced pain, spasticity or epileptic attacks have never been observed in these 
studies [73]. Several antibodies with different epitope specificities for the rat and human Nogo-A 
have been used in preclinical and clinical research. Table 2 summarizes these antibodies, their 
epitopes, and types. 
Another function of Nogo-A, potentially contributing to its ability to enhance recovery from CNS 
injury is its involvement in synaptic plasticity. These processes are mainly dependent on neuronal 
Nogo-A. Dendritic as well as synaptic spine architecture was shown to be influenced by Nogo-A and 
NgR1 signaling in the hippocampus [74]. Long term potentiation of hippocampal and cortical 
synapses was increased when Nogo-A or NgR1 were inactivated [75-77]. Furthermore, genetic 
deletion of the Nogo receptor family NgR1, NgR2, and NgR3 revealed an important role of Nogo-A as 
a brake on synapse formation in development [78].  
5. The role of Nogo-A in neuro-inflammatory and demyelinating 
conditions 
In recent years, the idea has been presented that Nogo-A may play a regulatory role in animal 
models of neuroinflammatory diseases and may thus be considered a potential therapeutic target for 
MS. Its abundant presence in myelin and myelin debris around acute and chronic MS lesions could 
restrict axonal regrowth as well as efficient myelin repair (Fig. 1). This hypothesis is supported by a 
considerable amount of studies from different laboratories using different animal models of MS and 
strategies for Nogo-A-neutralization. Moreover, there are supportive data on Nogo-A in MS patients. 
For a comprehensive molecular review on Nogo-A and MS, see Lee and Petratos [79]. 
Pioneering work by Karnezis and colleagues showed an important role of Nogo-A in the mouse model 
of autoimmune inflammatory CNS disease experimental autoimmune encephalomyelitis (EAE) [80]. 
They suppressed Nogo-A either by vaccination against Nogo-A or gene deletion. They found lower 
clinical scores and slower disease progression as well as reduced histological inflammation, 
demyelination and axonal damage. The reduced axonal pathology correlated well with the reduction 
in the severity of clinical disability and EAE progression. At the immunological level, vaccination with 
Nogo-A induced a shift in the production from pro-inflammatory Th1 to anti-inflammatory Th2 cells. 
The latter observation has not been reproduced so far, however. 
The immune response to vaccination of EAE susceptible mice with Nogo-A peptides, representing 
different epitopes of the extracellular Nogo-A domain Nogo-66, revealed that some epitopes were 
encephalitogenic while others ameliorated established EAE [81]. These effects appeared to be 
mediated by Nogo-66-specific T cells. 
Fontoura and colleagues [82] found that intravenous application of anti-Nogo-A IgG after EAE 
induction with MOG led to the prevention of disease onset for up to 12 days after the treatment was 
stopped. Compared to PBS or control IgG injections, the anti-Nogo-A IgG treatment decreased the 
incidence and severity of EAE and also blocked the progression of the disease. 
Blocking Nogo-A by means of neutralizing antibodies has also been shown to enhance recovery in 
established neuro-inflammation [83]: An improved clinical as well as anatomical outcome, i.e. 
reduced levels of axonal degeneration shown with the marker P-CRMP-2, was shown after 
therapeutic administration of anti-Nogo-A antibodies during the course of EAE in mice. 
Better clinical outcome in EAE was also observed by using a different way of Nogo-A suppression, 
namely by genetic knock down with small interfering RNA (siRNA) [84]. In vitro and in vivo, Nogo-A 
knock down led to higher levels of the growth-associated protein 43 (GAP43) in neurons [85]. This 
indicates that axonal repair was enhanced by suppressing Nogo-A. Interestingly, using this gene-
knock-out approach, the proliferation and cytokine production of myelin-specific T cells were 
unaltered suggesting that enhanced axonal regeneration could be the mechanism for the improved 
clinical recovery. This could be in line with observations in spinal cord injury and stroke models in 
which Nogo-A-suppression led to enhanced fiber growth and plasticity. Axonal regeneration could, at 
least in part, be responsible for functional recovery at an early MS disease stage, e.g. in the remission 
phases [86]. These plastic compensatory strategies of the CNS, e.g. by sprouting of surviving axons, 
formation of compensatory circuits or recruitment of reserve pathways, have been shown in animal 
models of stroke [72], spinal cord injury [87], as well as neuro-inflammatory pathology [88]. 
Interestingly, Nogo-A mRNA and protein levels were observed to be inversely correlated with those 
of the axonal growth marker GAP43 at different stages of the course of EAE [89]. This work showed 
that Nogo-A mRNA expression is reduced at preclinical and acute phases, which is followed by 
upregulation of mRNA and protein during the chronic EAE stage. In contrast, GAP43 was upregulated 
during acute EAE and downregulated in chronic EAE, often in close spatial proximity to Nogo-A 
mRNA/protein. The reduction of Nogo-A expression within an active inflammatory lesion therefore 
could facilitate axonal sprouting, whereas the higher levels of Nogo-A in the chronic lesions could 
impede neurite growth.  
The pre-clinical assessment of potential therapies for progressive MS is hampered by the fact that no 
animal models are available for mimicking the progressive MS disease course [18]. Most models fail 
to reproduce the complexity of the processes which define progressive MS, e.g. widespread microglia 
activation, chronic oxidative injury, subpial demyelination and cortical pathology at the same time 
[18]. Moreover, some models that claim to present a progressive phenotype, e.g. immunizing Biozzi 
ABH mice with spinal cord homogenate and complete Freund’s adjuvant [90], reflect stable disease 
on a high level of disability rather than true progression. 
Chronic demyelination is an important hallmark of progressive MS. Therefore, toxin-induced 
demyelination models are increasingly used to define therapies aiming at enhancing remyelination, 
e.g. lysolecithin, ethidium bromide, or cuprizone [91]. Results from such studies suggest that Nogo-A 
may also be involved in myelin repair in addition to possible immune modulatory and regeneration-
enhancing effects. Studies on myelin development in vitro and in vivo [67] showed that, by acting as 
a repulsive cue, Nogo-A influences and regulates the periodic, non-overlapping arrangement of 
myelin internodes along axons as well as their number and internodal distances [67]. By genetically 
deleting Nogo-A in oligodendrocytes, the relevance of this hypothesis was tested in vivo in spinal 
lysolecithin-induced demyelinating lesions. Interestingly, Nogo-A-deficient mice showed enhanced 
myelin repair compared to control mice. The amount of myelinating oligodendrocytes was 
unchanged within the demyelinated lesion. This strongly supports the hypothesis of an increased 
myelinogenic potential of the Nogo-A deficient oligodendrocytes, i.e. Nogo-A-deficient 
oligodendrocytes can form more myelin internodes around axons. Therefore, the neutralization of 
Nogo-A by antibodies can potentially be exploited to enhance remyelination. The involvement of 
Nogo-A and its receptors during myelin formation is supported by several other developmental in 
vitro and in vivo studies [92-94]. 
In a clinically relevant approach using antibody mediated Nogo-A-neutralization, subsequent to 
lysolecithin lesions in adult rat spinal cords, our lab obtained evidence for enhanced myelin repair as 
a consequence of this treatment (unpublished observations). Of note, the antibody mediated 
neutralization of LINGO-1, a component of the NgR1-Nogo-A receptor complex, also led to enhanced 
oligodendrocyte precursor cell differentiation during primary myelination as well as during myelin 
repair in different in vivo MS animal models [95-97]. In contrast, over-expression of LINGO-1 
impeded this precursor differentiation and abolishing myelin repair [98]. These (re-)myelination 
promoting effects are potentially also mediated by RhoA downstream signaling [95], but other 
signaling cascades were as well shown to be involved [98] (Table 1). 
The potential of antibodies directed against myelin antigens to promote remyelination has already 
been shown (reviewed in [99]). Murine as well as human anti-myelin antibodies were able to boost 
remyelination in rodent MS models. The proposed mechanisms were either involving removal of 
myelin debris after injury or direct effects on oligodendrocyte precursor cells. 
6. The role of Nogo-A in multiple sclerosis 
In addition to these preclinical studies, Nogo-A has also been examined in MS. Nogo-A was found to 
be upregulated in surviving oligodendrocytes in chronic active demyelinating lesions of MS patients 
[100]. This is consistent with findings in EAE mice [89]. Elevated serum and cerebrospinal fluid (CSF) 
autoantibody levels against the large N-terminal domain of Nogo-A have been found in blood 
samples from MS patients [101], but anti-Nogo-A antibodies exist also in healthy controls. The levels 
of these antibodies were reported to be increased in RRMS patients compared to chronic-progressive 
MS patients. Additionally, these anti-Nogo antibodies were more frequent in younger MS patients 
compared to older ones [101]. The role(s) of these Nogo-A-antibodies is currently unclear; they could 
reflect the ongoing auto-inflammatory processes against myelin including Nogo-A. Whether some of 
these antibodies could participate in reparative functions myelin or axons remains to be determined. 
7. Nogo-A-antibodies in clinical trials 
The experimental data from studies using different MS animal models and the exploratory data from 
MS patients which have been summarized above suggest Nogo-A-antibodies as a potential 
therapeutic agent for the treatment of RRMS and/or progressive forms of MS. Two phase 1 studies 
for Nogo-A-antibodies were recently conducted in patients with RRMS (ClinicalTrials.gov, 
NCT01424423 and NCT01435993). Both studies, with a very limited number of patients, have been 
terminated, but their results are not fully published yet. In its online clinical study register, 
GlaxoSmithKline states that the reasons for termination were unrelated to safety issues of the 
antibody treatment. 
Two phase 1 studies to assess acute safety, tolerability and pharmacokinetics of anti-Nogo-A 
antibodies were successfully completed in two other CNS diseases: one after intrathecal 
administration of anti-Nogo-A antibodies over 30 days in patients with acute spinal cord injury 
(NCT00406016; Kucher et al., in preparation), and another trial using very high doses of intravenously 
infused antibodies in patients with amyotrophic lateral sclerosis (ALS, NCT00875446) [102]. Both of 
these trials showed excellent safety and tolerance of the Nogo-A-antibody treatment. A phase 2 
study including more than 300 patients with ALS who were randomised to either anti-Nogo-A 
antibodies or placebo further showed that there was no apparent imbalance between treatment 
groups in adverse events (NCT01753076). Placebo-controlled multicentric phase 2 proof-of-principle 
studies are currently in preparation for spinal cord injury. 
An antibody against a Nogo-66 receptor associated component, LINGO-1 (opicinumab), has been 
tested in phase 1 and 2 studies in patients with RR-/progressive MS or with optic neuritis. High doses 
of i.v. antibodies were well tolerated [103] . In a phase 2 study in acute optic neuritis patients treated 
with anti-LINGO-1, vision did not improve after 8 months, but the velocity of nerve conduction, as 
measured by visually evoked potentials (VEP), was up to 41% less reduced compared to placebo 
treatment [104]. Since the latency of the VEP primarily reflects intact myelin sheaths, these data are 
interpreted as a sign of preserved myelin sheaths or remyelination. The failure to meet the 
secondary outcome of attenuation of the loss of retinal nerve fibers by optical coherence 
tomography indicates that retinal neurons and/or axons were lost despite of the anti-LINGO-1 
treatment. However, these interpretations are preliminary and await further confirmation. 
A very recent press release from a phase 2 study using monthly i.v. anti-LINGO-1 for relapsing and 
progressive MS did not meet its primary endpoint, a multicomponent analysis evaluating motor and 
cognitive function as well as disability (http://media.biogen.com/press-release/investor-
relations/biogen-reports-top-line-results-phase-2-study-opicinumab-anti-lingo). The opicinumab 
infusions were combined with a concurrent interferon beta add-on therapy. A potential reason for 
this failure despite promising pre-clinical results could be the ambitious and complex trial design. It 
used a complex multicomponent readout as primary endpoint including the Timed 25-Foot Walk 
(T25FW), the 9-Hole Peg Test (9HPT), and the Expanded Disability Status Scale (EDSS). The latter two 
tests have received criticism for being insensitive outcome measures for progressive MS trials [16]. 
EDSS is an ordinal scale, therefore, the statistical comparison between contiguous scores is 
insensitive. Moreover, scores can show high differences between different raters [105]. The 9HPT 
has floor and ceiling effects limiting its use for progressive MS trials. The patient collective was also 
very heterogeneous consisting of RRMS and SPMS patients further complicating final interpretations 
of the preliminary published study results. Full study results including subgroup analysis of RRMS vs. 
SPMS patients will be available in the next few months and will bring further clarification. 
8. Clinical aspects of a Nogo-A-antibody therapy 
8.1. Requirements for novel MS therapies 
As summarized above, a number of trials to achieve a therapeutic effect in progressive MS are 
currently ongoing. Experience from previous trials points to different requirements which need to be 
fulfilled by new therapies [25]: first, on-going or new inflammatory activity needs to be blocked, and, 
if possible, the compartmentalized intra-CNS chronic activation of microglia should be inhibited as 
well. Second, neuro- and/or myelin protection should be achieved to inhibit the above mentioned 
mechanisms that contribute to neuronal decline in the progressive disease stage. Third, given the 
presumable intrathecal compartmentalization of inflammation in the progressive stage, a potential 
drug needs to reach the CNS tissue in spite of a mostly intact BBB [25, 106], e.g. by intrathecal 
application [107], or delivery into the CSF space via a shuttle system. Intrathecal application leads to 
locally maximized drug concentrations with low systemic exposure and can therefore be expected to 
have minimal systemic side effects [107]. Fourth, besides immunomodulation and neuro-/myelin 
protection, the regenerative effects of treatments like anti-Nogo-A should foster repair as much as 
possible in this phase of disease. Fifth, the different pathogenic mechanisms in the progressive 
disease may require combinatorial therapies tackling the different targets of the degenerative 
process as well as various repair processes like axonal sprouting and myelin repair [16]. Sixth, and 
critical for testing the effects of such single or combination therapies, the most informative patient 
subgroups should be identified, and suitable trial designs including imaging readouts and biomarkers 
for degeneration and repair need to be applied. 
Under these assumptions, neutralization of Nogo-A seems a feasible and promising therapeutic 
strategy for the progressive disease stage of MS. As summarized above, a number of pre-clinical 
studies, mainly in the rodent EAE and lysolecithin model, and different ways of inhibiting Nogo-A 
showed functional as well as anatomical recovery in terms of axonal sparing, sprouting and myelin 
repair [67, 80, 83, 84]. One study also showed a beneficial immunomodulatory function of Nogo-A-
inhibition shifting the cytokine profile of T cells from a pro- to an anti-inflammatory one [80]. An anti-
Nogo-A therapy could therefore tackle two or even three of the major pathogenic hallmarks of MS 
(Fig. 1b, c, and e). NgR1/Lingo-1 inhibition has also been proposed as an approach to abolish Nogo-A-
signaling in MS [79]. Disappointing results of clinical trials investigating growth factors such as BDNF, 
NGF, CNTF, PDGF, or GDNF suggest that targets should be tissue- and cell type-specific. None of the 
other MS drugs, either still in development or already clinically approved, have CNS-specific targets. 
Therefore, both Nogo-A-antibodies and LINGO-1-antibodies are promising agents due to their high 
CNS target-specificity. In addition, it seems plausible that Nogo-A is present in the myelin debris in 
MS plaques prior to macrophage clearance thereby limiting the potential of these plaques for axonal 
repair. This myelin debris-associated Nogo-A could in fact be an important target of the Nogo-A-
antibodies to achieve axonal repair in MS. Moreover, the engulfment of myelin debris, potentially 
ameliorated through opsonization by Nogo-A-antibodies, could enhance remyelination [79]. 
8.2. Pharmacological aspects of Nogo-A-antibody therapy 
Perhaps the greatest concern of the Nogo-A-antibody therapy is its potential limited access to the 
CNS through the BBB, especially in progressive MS in which the disease process is compartmentalized 
behind a mainly intact BBB [25]. 
Preclinical data from a rat stroke model in our laboratory revealed that about 0.1% of a blood infused 
anti-Nogo-A antibody reached the CSF 7 days after i.v. bolus infusion (unpublished observations). 
This is consistent with trials in mouse EAE using an IgG [108] and in naïve rats using an anti-LINGO-1-
IgG [109]. 
Data from clinical trials support this notion. A study investigating the CSF concentration of rituximab 
after i.v. application in two MS patients (one with progressive disease) revealed 0.1 – 0.25% of this 
antibody being present in the CSF 24 weeks after application [110]. More evidence comes from 
clinical trials with LINGO-1-IgG [111] and rHIgM22 antibody [112]. Data from a pharmacokinetic study 
with rHIgM22 show that it was found in the brain of 14/14 patients after 2 days and in 5/12 patients 
after 29 days following intravenous infusion of a single dose. This IgM antibody is 5 times larger than 
IgG such as the LINGO-1- or Nogo-A-antibody. In the phase 1 study with i.v. anti-LINGO-1 in 72 
healthy volunteers or in 47 patients with either relapsing or progressive MS, doses of ≥ 10 mg/kg 
resulted in CSF concentrations of this antibody which were associated with 90% of the maximum 
remyelination effect in rat remyelination studies [103]. It seems therefore plausible that sufficient 
amounts of antibodies can cross the BBB when very high i.v. doses are administered. 
8.3. Potential “Off-target” effects of Nogo-A-antibodies 
Both, animal models and human observations have linked Nogo-A and NgR1 to schizophrenia 
(reviewed in [113]). Genetic association studies have identified Nogo-A and NgR as risk 
polymorphisms for neuropsychiatric disorders such as schizophrenia [114]. Besides this, mice lacking 
Nogo-A or NgR1 demonstrate behavioral phenotypes reflecting aspects of schizophrenia, e.g. deficits 
in prepulse inhibition (PPI) [115, 116]. Neurodevelopmental mechanisms seem to be responsible for 
this. In line with this, schizophrenic phenotypes have never been observed in rodents [115, 117] or 
primates [73] during or after therapeutic Nogo-A-antibody application. 
Nogo-A restricts neuronal plasticity and fiber growth in the adult CNS. Inhibition of this protein by 
antibodies could therefore potentially lead to aberrant fiber growth and wiring causing e.g. chronic 
pain or dyskinesia. These pathologies were, however, not observed in the trials for ALS [102] and 
spinal cord injury (NCT00406016; Kucher et al., in preparation) or in adult spinal cord injured rats [68] 
or primates [73] under Nogo-A-antibody therapy. 
9. Conclusions 
Axonal degeneration and chronic demyelination are hallmarks of chronic, slowly progressing MS. 
Preclinical studies in rodent EAE models showed that suppression of the growth inhibitory CNS 
protein Nogo-A, e.g. by neutralizing anti-Nogo-A-antibodies, enhance axonal sprouting and 
regeneration as well as the formation of new, functional circuits. Also myelin repair was enhanced 
after genetic deletion of Nogo-A in the lysolecithin myelin lesion model. Based on these data, anti-
Nogo-A antibodies could be a promising new therapy for relapsing as well as progressive MS. Phase 1 
and 2 studies with anti-Nogo-A-antibodies are currently under way for other neurological indications. 
The time seems ripe to test these antagonists of the Nogo-A – Nogo receptor pathway as novel 
therapeutic agents for relapsing and in particular progressive MS. 
  
Tables 
Table 1 Differences between the Nogo-A-antibody and the LINGO-1-antibody. 
 Anti-Nogo-A-antibodies Anti-LINGO-1-antibodies 
Target Nogo-A LINGO-1 
Expression Neurons and oligodendrocytes, 
oligodendrocyte precursor cells (OPCs) 
Neurons and oligodendrocytes, 
OPCs 
Receptors for ligands Sphingosine-1-phosphate receptor 2 
(Nogo-A-∆20), NgR1-LINGO-1-p75 
receptor complex (Nogo-66), Paired 
Immunoglobulin-like receptor B (PirB) 
Nogo-A, oligodendrocyte-myelin 
glycoprotein (together with p75 and 
NgR1), other unknown ligands 
Downstream signaling Ras homolog gene family member A 
(RhoA) 
RhoA, protein kinase B (Akt), other 
downstream signaling unknown 
Beneficial effects in 
pre-clinical animal 
models 
Promoting axonal sprouting and 
regeneration 
Enhancing remyelination 
Modulating immune response in 
neuro-inflammation 
Enhancing remyelination by 
improving oligodendrocyte 
differentiation. 
Promoting axonal repair. 
Other animal models in 
which the therapy 
showed beneficial 
effects 
Stroke, spinal cord injury, traumatic 
brain injury, optic nerve injury, 
amyotrophic lateral sclerosis (ALS) 
Glaucoma, Parkinson’s disease, 
spinal cord injury 
Presumable indication 
spectrum in MS 
Relapsing and progressive MS Relapsing and progressive MS 
Current clinical phase in 
MS 
Phase 1 Phase 2 completed (optic neuritis) 
 
Table 2 Target regions and antibody types of monoclonal Nogo-A-antibodies in preclinical and clinical 
research. The protein Nogo-A has two inhibitory domains, Nogo-A-Δ20 (amino acids 544–725 in rat 
Nogo-A) and Nogo-66 (amino acids 1055-1079 in rat Nogo-A, links the two long hydrophobic 
stretches which span the cell membrane). 
Antibody Target amino acids of Nogo-A Target region Antibody type 
11C7 [118] 623-640 (rat) Nogo-A-Δ20 Mouse IgG1 
11A8 [118] ~209-233 (rat) N-terminal extracellular part Mouse IgG1 
3D11 [118] ~910-920 (rat) N-terminal extracellular part Mouse IgG1 
7B12 [118] ~763-820 (rat) N-terminal extracellular part Mouse IgG1 
IN1 [119] Not specified - Mouse IgM 
ATI-355 
(NCT00406016) 
345-354 (human) N-terminal extracellular part Human IgG4 
Ozanezumab 
[102] 
610-621 (human) Nogo-A-Δ20 Humanized IgG1 
 
  
Figure legends 
Fig. 1 Receptors and downstream signaling of Nogo-A and potential mechanism(s) of Nogo-A-
antibody therapy in multiple sclerosis (MS). 
(a) The myelin-associated protein Nogo-A has two inhibitory regions, Nogo-66 and Nogo-A-Δ20. 
Nogo-66 binds to Nogo-receptor 1 (NgR1) which forms a complex with LINGO-1, p75, and/or TROY. 
Sphingosine-1-phosphate receptor 2 (S1PR2) has recently been identified as a Nogo-A-Δ20 receptor 
[58]. 
(b) In acute MS lesions, the attack of the myelin sheath by immune cells leads to demyelination. The 
myelin-associated protein Nogo-A is then present in the myelin debris potentially limiting 
axonal/myelin repair in MS plaques. 
(c) In acute and chronic MS lesions, neuronal/axonal degeneration can be very prominent. Nogo-A, 
present in the myelin debris and surrounding myelin sheaths, limits regeneration and compensatory 
sprouting of these damaged axons. Blocking Nogo-A with antibodies potentially leads to regeneration 
of axons and restoration of compensatory neuronal circuits. 
(d) Signaling cascade upon binding of Nogo-A to its cognate receptors: neuronal S1PR2 as well as the 
NgR1-LINGO-1-p75/TROY receptor complex activates RhoA and RhoA-Associated Kinase (ROCK). 
Different downstream targets including the phosphorylation of collapsin response mediator protein 2 
(CRMP-2) [83] lead to a disassembly of the actin and microtubule system with subsequent 
detrimental collapse of the growth cone. 
(e) After demyelination, oligodendrocyte precursor cells are recruited and differentiate into 
oligodendrocytes to remyelinate the naked axon. As suggested by recent evidence [67], Nogo-A 
seems to limit the myelinogenic potential of oligodendrocytes: oligodendrocytes from Nogo-A-
deficient mice can form an increased amount of myelin internodes. Nogo-A mediated repulsive 
interactions would lead to spatial segregation at Ranvier node formation. Remyelinated myelin 
sheaths are characteristically thinner than original myelin sheaths. 
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